Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...
The good news is that the risk for thyroid cancer linked to GLP-1 drugs appears low, but higher detections in the first year, ...
The study of more than two million veterans with diabetes details GLP-1 RA use relating to 175 outcomes; without ...
People who take weight-loss drugs based on GLP-1 receptor agonists seem to have reduced risk for a litany of diseases, ...
Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders ...
Blockbuster weight loss drug Ozempic could get cheaper by 2027, as it's on the list of medications the government is ...
Learn how diabetes medications could revolutionize stroke prevention and enhance heart and brain health with breakthrough ...
News Medical on MSN8d
Researchers create an atlas of health associations for GLP-1 receptor agonistsInsights from a study on GLP-1 receptor agonists reveal benefits for cardiometabolic health, with notable risks for ...
HealthDay News — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term, according to a study published online January ...
Adults with type 2 diabetes using a GLP-1 drug have a similar risk for thyroid cancer as those using other diabetes drugs, though increased thyroid cancer risk was observed in the first year after GLP ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback